Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Statement

27 Jan 2010 07:00

RNS Number : 1723G
Plant Health Care PLC
27 January 2010
 



For release: 7am, 27 January 2010 

 

PLANT HEALTH CARE PLC

("Plant Health Care" or "the Company")

Trading Update

Plant Health Care (AIM: PHC.L), a leading provider of naturally derived products to the agriculture and landscape industries, provides the following post year end update for 2009, ahead of the announcement of its full year results, which is expected on 15 February 2010.

The Company is pleased to announce that it has continued to make excellent progress with its strategic priorities, particularly in its relationships with Monsanto and Scotts. Furthermore, despite difficult trading conditions in the United States as a result of the recessionary economic climate and following the pre-tax loss of $3.9 million incurred in the first half of the year, the Company has traded profitably in the last six months. In consequence, the Company expects to report a significantly reduced full year lossin line with market expectations.

The Company has continued to make excellent progress in its partnership with Monsanto with significantly larger orders placed for Harpin (for use on Soybean), during 2009, than had originally been expected. Moreover, it continues to be in discussions regarding the use of Harpin on other crops than soybean and remains confident of reaching a conclusion to those discussions before the end of the Summer, with a consequent positive impact on the company's earnings in 2010.

As relationships with the Company's major customers have developed it has become clear that in the future, they will wish to align the timing of their purchasing of Harpin and other products more closely with their use. The Board is therefore adjusting its market guidance for 2010, and beyond, to recognise that at least one third of sales previously expected to fall in 2010 are now likely to fall in to the following year.

The cash position as at 31 December 2009 was $15.9 million (2008: $7.3 million), benefitting from tight cash management and the £10.5 million of new funds raised from the placing in May 2009.

The Company continues to be in advanced discussions with a wide variety of potential partners for both Harpin, as a foliar spray in combination with herbicides and fungicides, and for Myconate and remains confident that it will be in a position to conclude partnership deals on both these products before the end of 2010. 

John Brady, Chief Executive of Plant Health Care said: "2009 was an excellent year for Plant Health Care. For the first time one of our natural technologies will be on millions of acres and interest in our sustainable, naturally derived technologies is high. I look forward to providing more detail to our shareholders in February.

-Ends-

For further information please contact:

Plant Health Care plc

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

Evolution Securities

Tavistock Communications 

Tim Worlledge / Tim Redfern

Jeremy Carey/Matt Ridsdale

Tel: +44-20-7071-4300 

Tel: +44-20-7920-3150

tim.worlledge@evosecuties.com/

tim.redfern@evosecuties.com

jcarey@tavistock.co.uk

mridsdale@tavistock.co.uk


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFVALFIRFII
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.